Log in

CINP Council 2018 - 2020

The CINP Councillors are another piece to the CINP puzzle and play various key roles within the college. They are also all members of a CINP committee and contribute their valuable knowledge to improve the standards of the Neuropsychopharmacology on a day to day basis.

Prof. Helena Calil, Brazil

Prof. Dr. Helena Maria Calil is Vice President of Association Fund of incentive to Research and serve office as Councilor and member of two committees at CINP.

Dr Calil, graduated from medical school at the Faculdade de Ciências Médicas da Santa Casa de Sao Paulo; got a PhD in Pharmacology (concentration area: Psychopharmacology) from Escola Paulista de Medicina, both in Sao Paulo, Brazil. Pos-Doctor at Stanford University, and National Institute of Mental Health (Clinical Psychobiology Branch), both in the USA. Private-docent in Clinical Psychiatry, Department of Psychiatry, University Federal of Sao Paulo (UNIFESP, 1996). Professor of Psychopharmacology, Department of Psychobiology, (UNIFESP,1999).

Dr. Calil’s main areas of interest are Psychobiology of Mood Disorders), and most of her scientific contribution (scientific papers, book chapters, informative folders, editorials, and lay public information through radio, newspapers, and television. She has also been on the Editorial Board of national and international periodicals). Furthermore, she has received several awards, research grants, and has been consultant to World Health Organization (WHO), several research funding agencies and pharmaceutical industries.

Dr. Calil became also interested and very active with Mental Health advocating groups, serving offices at the Brazilian Association of Family, Friends and People with Affective Illness (ABRATA), later becoming its President; Member, Scientific Board, Fênix - Association Pro-Mental Health, Brazil.

Prof. Dr. Calil is founding member of the: Brazilian Society of Psychobiology (now Society of Neuroscience and Behavior; Latin-American College of Neuropsychopharmacology (Past-President and member of its Consultant Council), Brazilian Association of Bipolar Disorders. She was member of Society of Biological Society, USA, and Society of Light Therapy and Biological Rhythms.

Member of the Brazilian Association of Psychiatry ( served several offices, Past-Editor of its journal, now Revista Brasileira de Psiquiatria, and presently  a consultant to its Executive Committee).

Prof. Ryota Hashimoto, Japan

Dr. Ryota Hashimoto is a director, Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Japan (2018~).  Dr. Hashimoto graduated Osaka University School of Medicine (1995) and was a resident of Department of Psychiatry, Osaka University Hospital (1996). After he got a PhD in Psychiatry from Osaka University (2000), he was a post doc at National Institute of Mental Health, NIH (Section of Neurobiology and Clinical Brain Disorder Branch) in USA (2000-2003). Dr. Hashimoto worked as a researcher and psychiatrist at Section Chief in Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan (2003-2006) and then Associate professor in Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University (2006-2018).

Dr. Hashimoto is investigating the diagnostic and therapeutic methods of mental illnesses including schizophrenia, mood disorders and autism spectrum disorders using neuropsychological, neurophysiological, neuroimaging, neuropsychopharmacological, and genetic methods using large database and research resource with 4000 subjects he collected at Osaka University. Dr. Hashimoto spearheads Cognitive Genetics Collaborative Research Organization (COCORO), which consists of 39 leading institutes of biological psychiatry in Japan. Dr. Hashimoto also a member of creating clinical practice guidelines, Pharmacotherapy of Schizophrenia and Major Depressive disorder in Japan, and developed “EGUIDE (Effectiveness of GUIdeline for Dissemination and Education in psychiatric treatment) project” to spread clinical practice guidelines for improvement of quality of medical care in psychiatry, which consists of 94 hospitals in psychiatric fields.

Prof. Katharina Domschke, Germany

Katharina Domschke, MA, MD, PhD, is Full Professor of Psychiatry and Chair of the Department of Psychiatry and Psychotherapy, University of Freiburg, Germany.

She completed her studies in medicine and psychology at the University of Muenster, Germany, and Trinity College Dublin, Ireland (M.D., 2004), as well as Boston University, Boston, MA, USA (M.A., 2002), and Maastricht University, The Netherlands (Ph.D., 2010). After her board certification as a psychiatrist she worked as an attending physician and associate professor at the Dept. of Psychiatry, University of Muenster, Germany. In 2012, she was appointed Full Professor of Psychiatry and in 2014 Vice Chair of the Dept. of Psychiatry, University of Wuerzburg, Germany. Since 2016, she is Chair and Full Professor at the Dept. of Psychiatry, University of Freiburg, Germany, and Adjunct Professor at the Medical University of Vienna, Austria.

Her clinical and teaching focus is on depression, anxiety, OCD and PTSD. Scientifically, Prof. Domschke is a renowned expert in genetics, epigenetics, imaging genetics and therapygenetics of anxiety and depression as reflected by to date ~200 publications in international journals and 25 book chapters.

Her work has been recognized by e.g. the WFSBP Research Award, the WPA Fellowship Award and the ECNP Fellowship Award. Prof. Domschke has received funding from the EU, the German Research Foundation (DFG) and the German Ministry of Research and Education (BMBF). She is a full member of ACNP, ECNP, ISPG, SOBP, the German Society of Biological Psychiatry (DGBP) and the German Society of Psychiatry, Psychotherapy and Neurology (DGPPN). Prof. Domschke serves on the editorial boards of e.g. the International Journal of Neuropsychopharmacology, Pharmacopsychiatry, Progress in Neuropsychopharmacology & Biological Psychiatry and the World Journal of Biological Psychiatry.

Prof. Jun Soo Kwon, Republic of Korea

Professor Jun Soo Kwon graduated from Seoul National University College of Medicine, Korea in 1984. He had been trained in Department of Psychiatry, Seoul National University Hospital and earned his Ph.D. from Seoul National University in 1993. Professor Kwon had been working with Robert W. McCarley and Martha E. Shenton in Department of Psychiatry, Harvard Medical School from 1996 through 1998, where he studied anatomical and functional abnormalities in schizophrenia with MRI and electrophysiological method.

His research interest includes the brain structural/functional changes with treatment using various brain imaging tools (MRI/fMRI/EEG/PET) in schizophrenia and obsessive-compulsive disorder. Now, he is especially interested in the early detection and prevention of high risk subjects of schizophrenia.

Professor Kwon received several academic awards, including Paul Janssen Schizophrenia Research Award from KNPA, 1st Academic Award from Korean College of Neuropsychopharmacology (KCNP), GSK Academic award and Siemens Human Brain Mapping Award.

Professor Kwon published about 300 papers including over 160 papers in the international journals. Now he is the professor in the Department of Psychiatry, Seoul National University College of Medicine, Interdisciplinary Program in Brain Science in Seoul National University, and Interdisciplinary Program in Clinical Pharmacology in Seoul National University. Recently, he is the unit leader of Clinical Neuroscience & Computational Anatomy Unit, Brain & Cognitive Science, funded by Korean Ministry of Education, Science & Technology.

He was in charge of the Chair of Scientific Committee in 2007 WPA regional meeting in Seoul, and the local chair of 2016 CINP Seoul Congress. Now, he is the President of Korean Neuropsychiatric Association and a Council member in CINP and AsCNP (Asian College of Neuropsychopharmacology).

Prof. Atsumi Nitta, Japan

Dr. Atsumi Nitta graduated with a BS degree in Pharmaceutical Sciences from Gifu Pharmaceutical University in 1990 and obtained an M.Sc. in Pharmacy from the same institute in 1992. She  received my Ph.D. in Medicine from Nagoya University in 1995. She began my research in the field of neuropsychopharmacology. As an Assistant Professor in the Laboratory of Molecular Biology at Gifu Pharmaceutical University (1995–2002), She gained experience in various molecule biology techniques and established enzyme immunoaasay systems to measure neurotrophic factors levels in mice or human brains and in cultured medium. She found that Leu-Ile is effective for animal models of spinal cord injury, Parkinson’s disease, and depression via neurotrophic factors inductions. In 2002,  She  was promoted to be the Assistant Professor and Vice Director of the Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine.  At Nagoya University, She joined new projects of drug addiction and schizophrenia as well as cognitive disorders both in the basic and clinical fields. I isolated new molecules associated with drug addiction and mental diseases. In 2009, She was promoted to be a full-Professor at the Department of Pharmaceutical Therapy & Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama. She is an appointed member for the Technical Committee of the Japanese Government, including the Ministry of Health, Labor and Welfare, and contribute to the education in School of Pharmacy to be high-level clinical pharmacists in Japan.

In these laboratories, she continued studies on addiction, schizophrenia, depression, dementia, and neurodevelopmental disorders at the molecular, genetic, animal-behavioral, and clinical levels. She has published more than 150 articles covering these topics in scientific journals, including Int. J. Neuropsychopharmacol., Proc. Natl. Acad. Sci., Mol. Psychiatry, and J. Neurosci. She was awarded the Distinguished Young Scientist (Japanese Society for Neurochemistry) in 2004, among several other awards.

Prof. Peter Falkai, Germany

Peter Falkai has been working in the field of psychiatry for 30 years. His main research interest is focused on the neurobiology of psychotic disorders, namely schizophrenia. He holds the position of Chair of the Department of Psychiatry and Psychotherapy of the University of Munich.

Prof. Falkai has been leading multidisciplinary teams of researchers, allowing the use of techniques ranging from functional imaging to gene expression in human post-mortem-tissue. His clinical and research expertise focuses continuously on the neurobiological origins and pathomorphological aspects as well as on causal treatment options of psychotic disorders.

Prof. Falkai has managed to obtain state funding for numerous of his research projects and has also received various research awards. He has been involved in creating treatment guidelines for schizophrenia for the German Society of Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and for the World Federation of the Biological Societies (WFSBP). He was Chairman of the DGPPN from 2011-2012 and Chairman of the Council of National Societies (NPAs) of the European Psychiatric Association (EPA) from 2012-2014.

Prof. Maurizio Fava, USA

Dr. Maurizio Fava is director, Division of Clinical Research of the Massachusetts General Hospital (MGH) Research Institute, executive vice chair of the Department of Psychiatry and executive director of the Clinical Trials Network and Institute, (MGH), and associate dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School.

Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored more than 900 original articles, cited more than 60,000 times in the literature and with an h index of over 125.

Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university. He then moved to the United States and completed residency training in psychiatry at MGH. He founded and was director of the hospital’s Depression Clinical and Research Program from 1990 until 2014. In 2007, he also founded and is now the executive director of the MGH Psychiatry Clinical Trials Network and Institute, the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry. Under Dr. Fava’s direction, the Depression Clinical and Research Program became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work.

Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $100,000,000. Dr. Fava’s prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression. He is also the former President of the American Society of Clinical Psychopharmacology.

Prof. Carol Tamminga, USA

Dr. Tamminga is a Professor, Chairman of Psychiatry and Chief of Translational Neuroscience Research in Schizophrenia at the University of Texas Southwestern Medical School.  She holds the Communities Foundation of Texas Chair in Brain Science along with the Lou and Ellen McGinley Distinguished Chair in Psychiatric Research.  She directs clinical and preclinical research in schizophrenia focused on identifying disease mechanisms and on improving treatments.  Dr. Tamminga graduated from Vanderbilt Medical School and completed a Psychiatry Residency at the University of Chicago and spent many years at the University of Maryland, MPRC, then moved to UT Southwestern Medical School to continue her research. Dr. Tamminga has been the recipient of numerous federal and foundation grants, as well as Award in the field.  She has served on the National Advisory Mental Health Council, NIMH and the Council of the National Institute of Drug Abuse.   Dr Tamminga was elected to the National Academy of Medicine in 1998 and has served on several IOM committees in that capacity.

The goal of Dr. Tamminga’s research is to examine and understand the mechanisms underlying schizophrenia, especially its most prominent symptoms, psychosis and memory dysfunction, in order to build rational treatments for the illness.  She evaluates the function of the living human brain in individuals with and without schizophrenia using brain imaging techniques.  Then, building on this knowledge, she uses human postmortem brain tissue to translate the functional alterations from the living human patient into molecular observations of the illness.  Now she is using case-specific neuronal cultures to address molecular and cellular questions.  Her ultimate goal is to use the alterations in in vivo imaging, postmortem molecular changes and cultured neuronal characteristics as biomarkers and targets for identifying animal models of disease and novel active pharmaceuticals for psychosis.    

Prof. Allan Young, United Kingdom

Professor Allan Young holds the Chair of Mood Disorders at King’s College London where he is also Director of the Centre for Affective Disorders within the Department of Psychological Medicine in the Institute of Psychiatry. He has held academic appointments at the Universities of Oxford, Newcastle upon Tyne (latterly holding the Chair of General Psychiatry at Newcastle), UBC, Vancouver, Canada, where he held the Leading Edge Endowment Fund Endowed Chair in Research in the Department of Psychiatry and was also the Director of the Institute of Mental Health and Imperial College London where he held the Chair of Psychiatry and was Director of the Centre for Mental Health.

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, the Stanley Medical Research Institute, and the Canadian Institutes for Heath Research (CIHR), the National Institutes of Health (USA) and numerous other funding agencies. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders including ‘Bipolar disorders: basic mechanisms and therapeutic implications’ (2nd Ed.) with JC Soares, and ‘Practical management of bipolar disorder’ with IN Ferrier and E Michalak (Cambridge University Press, 2010).

Professor Young is a member of a number of editorial boards and is a member of numerous professional and scientific societies. He is Immediate Past President of the International Society for Affective Disorders and the current President of the British Association of Psychopharmacology.

Prof. Gabriella Gobbi, Canada

Dr. Gabriella Gobbi is a Professor in the Department of Psychiatry, McGill University.

She leads a laboratory of basic science (Neurobiological Psychiatry Unit) and works as a Staff Psychiatrist at the Mood Disorder Clinic of the McGill University Health Center.

Her research approach spans from bench to bedside, bridging the gaps between fundamental and clinical research. Dr. Gobbi received her MD (1991) and her specialty in Psychiatry and Psychotherapy (1995) from the Catholic University of Rome (Italy). She also earned a PhD in Neuroscience at the University of Cagliari, Italy) and finalized a post-doc at McGill University (Montreal, Canada) in 1998.
Dr Gobbi’s lab is interested in understanding the pathophysiology of major depression and sleep related disorders and in the discovery of new treatments and cures for them.

In particular, her laboratory is studying the short- and long-term effects of cannabis use in mood and anxiety, and the potential beneficial effects of the drugs acting on the endocannabinoid system (endogenous cannabis) in the cure of mental diseases. Her lab is also studying the effect of melatonin in mood, anxiety and sleep regulation in an effort to understand how novel selective ligands for melatonin receptors (called MT1 and MT2 receptors) can be used to treat seasonal depression, major depression, sleep disorders, as well as pain.

Dr. Gobbi is author of more than 90 highly cited manuscripts in high impact journals, 20 book chapters, one book and holds two international patents in psychopharmacology.

She has received several fellowships for more than $10M as a principal investigator. She has won many prizes including the Canadian College of Neuropsychopharmacology (CCNP) Young investigator Award in 2012, the Venezia Prize in 2015 and the Sam Lal prize from the Boeckh Foundation in 2017. She has served as reviewer/editor for many journals, international grant agencies in Europe and the USA and has been invited to speak at conferences around the world.

©2019 CINP